Drug Patent Watch

FEBRUARY 5, 2025

The Latin American Pharmaceutical Market: Why Specialty Generics Are Poised for Growth As the pharmaceutical industry continues to evolve, one trend is becoming increasingly clear: the demand for specialty generics is on the rise, particularly in the Latin American market. What do you think is the future of the pharmaceutical industry?

Marketing 93

Marketing Manufacturing Development 93

Pharmaceutical Technology

JULY 1, 2024

On 8 May, the UK was the world's first government to formally implement a new model for the funding and support of novel antibiotic commercialisation.

Marketing 299

Marketing 299

Pharmaceutical Technology

JULY 22, 2024

As the use of AI soared across healthcare, NVIDIA fit the bill in providing the necessary technology – and its stock tells the same story.

Marketing 344

Marketing 344

Pharmaceutical Technology

MARCH 3, 2025

The EC has authorised the marketing of Bavarian Nordic's Vimkunya chikungunya vaccine for individuals as young as 12 years old.

Vaccine 162

Vaccine Vaccination Marketing 162

Bio Pharma Dive

JANUARY 17, 2024

The offering is the fifth outlined by a biotech startup this month, suggesting companies are becoming more willing to gauge investors’ appetite for new stock offerings.

Marketing 309

Marketing 309

Intouch Solutions

JANUARY 17, 2025

In a recent article published by Med Ad News , Mary Anderson, Senior VP, Managing Director and Head of MedComm at EVERSANA INTOUCH, highlighted the pivotal role medical communications (MedComm) has played in giving brands a leg up in a competitive market.

Marketing 59

Marketing Branding Trials 59

Pharmaceutical Technology

JUNE 28, 2024

On 17 June, Amylyx acquired the rights to Eiger Biopharmaceutical’s experimental GLP-1 receptor antagonist, avexitide, for $35.1m.

Marketing 264

Marketing 264

Bio Pharma Dive

JANUARY 19, 2023

“What we’re experiencing now is the aftershock of the party that went on for the last three years,” said Ovid CEO Jeremy Levin in a BioPharma Dive panel that included former Sage head Jeff Jonas and biotech entrepreneur Greg Verdine.

Marketing 334

Marketing Drugs 334

XTalks

DECEMBER 19, 2024

Roches Alecensa is the current ALK inhibitor market leader. The intracranial response rate, as confirmed by a blinded independent review committee, was 63.6 percent (seven out of 11) for patients treated with ensartinib compared to 21.1 Results from the drugs first-line eXalt3 study were published in JAMA Oncology over three years ago.

FDA Approval 98

FDA Approval Marketing Trials Drugs 98

Bio Pharma Dive

SEPTEMBER 26, 2024

The withdrawal comes as trial results indicate safety concerns with the drug, Oxbryta, which was first approved in the U.S.

Trials 274

Trials Drugs Marketing 274

Bio Pharma Dive

JULY 22, 2024

Private biotech company acquisitions are on their fastest pace in years, a trend some in the industry say is driven by the abundance of mature, but not yet public, drug startups.

Marketing 253

Marketing Drugs 253

Pharmaceutical Technology

OCTOBER 18, 2024

Late-stage pipeline products could drive combined sales of approximately $171.4 million by 2033 in the 8MM.

Sales 269

Sales Marketing Production 269

Pharma Marketing Network

MARCH 17, 2025

With increasing competition and stricter compliance regulations, pharma marketing teams must adopt data-driven and personalized marketing strategies to capture the attention of HCPs. But how can pharma brands stand out in a crowded market? For expert guidance on pharma marketing trends, visit Pharma Marketing Network.

Branding 52

Branding Marketing Compliance Pharma Companies 52

Pharmaceutical Technology

MARCH 6, 2025

The European orphan drug market is growing and is already comparable in size and scope to the US market.

Marketing 130

Marketing Drugs 130

Drug Patent Watch

JANUARY 30, 2025

Maximizing Patent Protection: Strategies for Pharmaceutical Marketers As a pharmaceutical marketer, you know how crucial it is to protect your patented drug's market share. In this post, we'll explore effective strategies for maximizing patent protection and exclusivity, ensuring your product remains a leader in the market.

Marketing 59

Marketing Drugs Production Sales 59

Pharmaceutical Technology

NOVEMBER 8, 2024

Leqembi is approved for Alzheimer’s patients in multiple territories, but questions remain over its cost-effectiveness.

Marketing 240

Marketing 240

Pharmaceutical Technology

FEBRUARY 12, 2025

EC has granted marketing authorisation to BridgeBio Pharmas acoramidis under the Beyonttra brand name for treating ATTR-CM.

Marketing 147

Marketing Branding 147

Drug Patent Watch

MARCH 18, 2025

In emerging markets, the struggle to provide quality healthcare is often hindered by the high cost of branded medications. In emerging markets, where healthcare budgets are often stretched thin, generics have been a lifeline for patients who might otherwise go without the treatments they need.

Generic Drugs 52

Generic Drugs Marketing Development Drugs 52

Pharmaceutical Technology

AUGUST 12, 2024

As antibody drug conjugate (ADC)-centred deals dominate the oncology space, biotechs are using newer targets and linkers to differentiate themselves.

Pharma Companies 264

Pharma Companies Antibody Marketing Drugs 264

Pharmaceutical Technology

JUNE 27, 2024

Data showed that Ohtuvayre significantly improved dyspnea compared to placebo in as little as six weeks and maintained this over 24 weeks.

Marketing 244

Marketing 244

Pharmaceutical Technology

MAY 2, 2024

Novo Nordisk noted a 22% boost in sales owing to increased sales of GLP-1 agonists and other obesity products.

Sales 246

Sales Marketing Production 246

AuroBlog - Aurous Healthcare Clinical Trials blog

OCTOBER 15, 2024

(Abdullah Durmaz/Getty Images) In just a few years, brand-name injectable drugs such as Ozempic, Wegovy, Mounjaro and Zepbound have rocketed to fame as billion-dollar annual sellers for weight loss as well as to control blood sugar levels and reduce the risk of heart disease. But the price of these injections is steep: They cost about […]

Marketing 246

Marketing Branding Drugs Clinical Trials 246

Pharmaceutical Technology

JULY 22, 2024

As the use of AI soared across healthcare, NVIDIA fit the bill in providing the necessary technology – and its stock tells the same story.

Marketing 245

Marketing 245

Intouch Solutions

MARCH 13, 2025

The rise of artificial intelligence (AI) has transformed the marketing landscape, enabling brands to personalize content, optimize campaigns, and reach audiences more efficiently than ever before. Submit your details below to access the POV. Download the POV Submit Your Details to Access the Content

Marketing 59

Marketing Branding 59

Pharmaceutical Technology

NOVEMBER 6, 2024

The top 20 biopharmaceutical companies demonstrated signs of recovery during the third quarter (Q3) of 2024 as investor optimism improved following the interest rate cuts by the US Federal Reserve in September 2024.

Marketing 263

Marketing Drugs 263

Pharmaceutical Technology

DECEMBER 5, 2023

Professor Timothy Mackey talks about the recent reports of fraudulent Ozempic pens and the challenges in chasing drug counterfeiters.

Drugs 278

Drugs Marketing 278

Pharmaceutical Technology

FEBRUARY 14, 2025

The Duchenne muscular dystrophy (DMD) landscape across the seven major markets (7MM) - the US, France, Germany, Italy, Spain, the UK, and Japan - is projected to experience significant growth, with sales increasing from $2.3bn in 2023 to $5.2bn by 2033, according to leading data and analytics company GlobalData.

Marketing 147

Marketing Sales 147

Pharmaceutical Technology

JANUARY 21, 2024

CDMOs, who cater to the requirements of multiple companies and develop platform processes to achieve the much-needed economy of scale, are being seen as a possible solution.

Manufacturing 246

Manufacturing Marketing Development 246

Bio Pharma Dive

FEBRUARY 2, 2023

The company’s lead drug could be an oral alternative to marketed diabetes and obesity drugs from Novo Nordisk and Eli Lilly.

Marketing 360

Marketing Drugs 360

Bio Pharma Dive

FEBRUARY 6, 2022

For the first time in years, biotechs no longer have an easy path onto Wall Street, a market reversal that could change what the next generation of young drugmakers looks like.

Drugs 364

Drugs Marketing 364

Bio Pharma Dive

MARCH 24, 2022

At least nine biotechs working in cell or gene therapy have announced layoffs, cost cuts or restructured their research since December — restructurings that have coincided with a stock market downturn.

Gene Therapy 361

Gene Therapy Gene Marketing Research 361

Bio Pharma Dive

SEPTEMBER 12, 2024

The offerings by Bicara, Zenas and MBX give a glimpse into what industry insiders describe as a backlog of mature startups waiting for the right opportunity to test public markets.

Marketing 327

Marketing 327

Bio Pharma Dive

NOVEMBER 11, 2024

Negative drug results cost AbbVie billions of dollars in market value and convinced analysts that Bristol Myers had placed a better bet in buying Karuna Therapeutics.

Drugs 321

Drugs Marketing 321

Bio Pharma Dive

NOVEMBER 3, 2022

In a panel discussion hosted by BioPharma Dive, venture capitalists and CEOs discussed how startups can navigate a challenging market as well as possible ripple effects from the new U.S. drug pricing law.

Marketing 362

Marketing Drugs 362

Bio Pharma Dive

MAY 13, 2024

Goldman Sachs and Eli Lilly are among those backing the startup, which claims its prospect could be more potent than the myelofibrosis therapies that have come to market in recent years.

Drugs 325

Drugs Marketing 325

XTalks

FEBRUARY 7, 2025

In the biotechnology sector, a biotech IPO occurs when a biotech firm lists its shares on a stock exchange, thereby attracting investment from public markets. An initial public offering (IPO) is the process through which a private company sells its shares to the public for the first time, transitioning into a publicly traded entity.

Marketing 66

Marketing Genetics Vaccination Vaccine 66

Bio Pharma Dive

FEBRUARY 17, 2023

Apellis’ Syfovre is the first marketed treatment for geographic atrophy, a common and irreversible eye condition. But questions linger about its benefit and safety.

FDA Approval 344

FDA Approval Drugs Marketing 344